Results 121 to 130 of about 120,930 (291)

The Feasibility and Practical Utility of Virtual Visits for Patients with Parkinson's Disease in Different World Regions

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Overcoming existing access barriers is crucial for better‐specialized health care of patients with Parkinson's disease (PD). Objective The aim of the study was to compare the access and visit quality/acceptability between in‐office and virtual telemedicine visits.
Álvaro García‐Bustillo   +11 more
wiley   +1 more source

Discordance of Dopaminergic Dysfunction and Subcortical Atrophy by α‐Synuclein Status in Sporadic and Genetic Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background Parkinson's disease (PD) is characterized by predominantly neuronal α‐synuclein pathology and dopaminergic dysfunction. Cerebrospinal fluid (CSF) seeding amplification assays (SAA) detect α‐synuclein aggregates in vivo, but not all patients with PD have a positive SAA.
Michael Tran Duong   +186 more
wiley   +1 more source

Academician M.I. Perelman. The 100th Anniversary

open access: yesТуберкулез и болезни лёгких
.
V. D. Parshin, I. A. Vasilyeva
doaj   +1 more source

Perelman singular manifolds

open access: yes
On a Riemannian manifold with a smooth function $f: M\to \mathbb{R}$, we consider the linearization of the Perelman scalar curvature $\mathcal{R}$ and its $L^2$-formal adjoint operator $δ\mathcal{R}^*$. A manifold endowed with a metric $g$ whose operator $δ\mathcal{R}^*$ has a nontrivial kernel is called a Perelman singular manifold.
Batista, Márcio   +2 more
openaire   +2 more sources

What Is Required for AI to Improve the Assessment and Treatment of Patients With Lower Urinary Tract Dysfunction? ICI‐RS 2025

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Artificial intelligence (AI) is poised to improve the diagnosis and management of lower urinary tract dysfunction (LUTD). Its effective deployment requires prioritization, regulatory oversight, rigorous validation, and clinician and patient engagement.
Glenn T. Werneburg   +15 more
wiley   +1 more source

Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium—Update for Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU)

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT The Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium, supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has had a successful and productive ten years, accomplishing several major achievements, including over 65 peer‐reviewed publications.
Ariana L. Smith   +2 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

open access: yesObesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu   +13 more
wiley   +1 more source

El sindicalismo en los Estados Unidos: sus características, desarrollo y problemas actuales

open access: yesRevista de la Facultad de Derecho, 2005
Esta breve examinación del sindicalismo norteamericano nolles una historia de los obreros sindicalizados en los Estados Unidos sino un estudio de las fuerzas y acontecimientos que han influido en su composición, dirección y objetivos.
Richard Perelman
doaj  

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

open access: yesObesity, EarlyView.
ABSTRACT Objective This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT‐1, SURMOUNT‐2, and SURMOUNT‐3. Methods In participants (N = 4056) treated with tirzepatide (5/10/15 mg or maximum tolerated dose 10/15 mg) versus placebo, depressive symptoms and suicidal ...
Thomas A. Wadden   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy